Dr. Sandip Ganguly

Senior Consultant

16 Years of Experience

Medical Oncologist

MBBS, MD, DM

Reg. No.:75102, West Bengal Medical Council

Apollo Gleneagles Hospital, Kolkata

English

Consultation Fee ₹ 1500

Book an Appointment

About Dr. Sandip Ganguly

Dr. Sandip Ganguly is a renowned Medical Oncologist with over 15 years of experience.
He specializes in treating breast cancer, cervical cancer, anal cancer, lung cancer, gastrointestinal cancer, thoracic cancer, gynecological cancer, etc.
He earned his MBBS and MD in General Medicine from Kasturba Medical College, Mangalore, in 2008 and 2011.
Later, in 2015, he specialized in cancer treatment by completing a DM in Medical Oncology from the Kidwai Memorial Institute of Oncology.
He is deeply committed to patient care and actively participates in global clinical trials and research initiatives.
Dr. Ganguly has numerous publications in esteemed medical journals and advocates passionately for patient assistance programs to ensure optimal cancer treatment outcomes.

Book Your Appointment With Dr. Sandip Ganguly

Get a Treatment Plan Within 1 Hour

Name*

Mobile Number*

Is the above number on WhatsApp? *

Yes

Query

Education

MBBS - Kasturba Medical College, Mangalore - 2008
MD - Kasturba Medical College, Mangalore - 2011
DM - Medical Oncology- Kidwai Memorial Institute of Oncology - 2015

Past Experience

Consultant Medical Oncologist Tata Medical Center - 2023
Resident, Medical Oncology Kidwai Memorial Institute Of Oncology - 2015
Senior Resident Kasturba Medical College, Mangalore - 2012

Paper Published

He has published over 123 articles. Some of them are:

Real-world study of safety and efficacy of erlotinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India – a multicentre chart review study (ROSELAND)
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
LBA11 Amivantamab plus chemotherapy vs. chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
287MO Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive
Amivantamab plus chemotherapy with and without lapatinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
272P Correlation of dihydropyrimidine dehydrogenase gene mutation with toxicity among gastrointestinal cancers (GI) taking 5-fluorouracil-based chemotherapy: Experience from a tertiary cancer center in the eastern part of India
272P Correlation of dihydropyrimidine dehydrogenase gene mutation with toxicity among gastrointestinal cancers (GI) taking 5-fluorouracil-based chemotherapy: Experience from a tertiary cancer center in the eastern part of India
Pancreatic Adenocarcinoma with Primary Tumor Calcification and Calcified Liver Metastasis: Report of a Rare Case and Review of Literature
Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over three weeks) with a novel 1-week schedule in adjuvant breast cancer: An open-label randomized controlled study (HYPORT-Adjuvant) - Study protocol for a multicentre, randomized phase III trial